Yondelis Is a Feasible Treatment for Soft Tissue Sarcoma Patients Regardless of Patient age: a Retrospective pooled Analysis of Five Phase II trials .

British Journal of Cancer , (10 September 2013) .

This retrospective pooled analysis assessed the effect of age on the efficacy and safety of trabectedin in young and elderly patients with recurrent advanced soft tissue sarcoma (STS).


...

Conclusion:

This analysis demonstrated that trabectedin is a feasible treatment in young and elderly patients with STS, with meaningful clinical benefits and an acceptable safety profile, essential in palliative treatment of elderly patients.

...